Phathom Pharmaceuticals is using ANMS2026 to showcase its first-in-class GERD therapy, a step to raise its profile in a competitive treatment market. The compan

Phathom Pharmaceuticals is using ANMS2026 to showcase its first-in-class GERD therapy, a step to raise its profile in a competitive treatment market. The company has scheduled a product theater for 12:05 p.m. in Minneapolis; further details remain limited.